Page 1332 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 94Ann A. Jakubowski

REFERENCES

1. Banna GL, Simonelli M, Santoro A. High-dose chemotherapy 15. Billingham RE. The biology of graft-versus-host reactions.
followed by autologous hematopoietic stem-cell transplantation Harvey Lect. 1966;62:21-78.
for the treatment of solid tumors in adults: a critical review. 16. Filipovich AH. Diagnosis and manifestations of chronic graft-
Curr Stem Cell Res Ther. 2007;2:65-82. versus-host disease. Best Pract Res Clin Haematol. 2008;21:251-257.
2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl 17. Griffith LM, Pavletic SZ, Lee SJ, Martin PJ, Schultz KR,
J Med. 2006;354:1813-1826. Vogelsang GB. Chronic graft-versus-host disease—
3. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after implementation of the National Institutes of Health Consensus
allogeneic hematopoietic-cell transplantation. N Engl J Med. Criteria for Clinical Trials. Biol Blood Marrow Transplant.
2010;363:2091-2101. 2008;14:379-384.
4. McCluskey J, Peh CA. The human leucocyte antigens and 18. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized
clinical medicine: an overview. Rev Immunogenet. 1999;1:3-20. trial comparing cyclosporine and short course methotrexate with
5. Giralt S, Bishop MR. Principles and overview of allogeneic cyclosporine and mycophenolate mofetil for GVHD prophylaxis
hematopoietic stem cell transplantation. Cancer Treat Res. in myeloablative allogeneic bone marrow transplantation. Bone
2009;144:1-21. Marrow Transplant. 2004;34:621-625.
6. Afessa B, Azoulay E. Critical care of the hematopoietic stem cell 19. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus
transplant recipient. Crit Care Clin. 2010;26:133-150. without methotrexate as graft-versus-host disease prophylaxis
7. Kew AK, Couban S, Patrick W, et al. Outcome of hematopoietic after matched related donor peripheral blood stem cell trans-
stem cell transplant recipients admitted to the intensive care plantation. Biol Blood Marrow Transplant. 2004;10:328-336.
unit. Biol Blood Marrow Transplant. 2006;12:301-305. 20. Alyea EP, Li S, Kim HT, et al. Sirolimus, tacrolimus, and low-
8. McArdle JR. Critical care outcomes in the hematologic dose methotrexate as graft-versus-host disease prophylaxis in
transplant recipient. Clin Chest Med. 2009;30:155-167. related and unrelated donor reduced-intensity conditioning
allogeneic peripheral blood stem cell transplantation. Biol Blood
9. Trinkaus MA, Lapinsky SE, Crump M, et al. Predictors of Marrow Transplant. 2008;14:920-926.
mortality in patients undergoing autologous hematopoietic
stem cell transplantation admitted to the intensive care unit. 21. Soiffer RJ. Hematopoietic Stem Cell Transplantation. 2nd ed.
Bone Marrow Transplant. 2009;43(5):411-415. Totowa, NJ, London: Humana;Springer distributor; 2008.
10. Scales DC, Thiruchelvam D, Kiss A, et al. Intensive care 22. Ferrara JL, Yanik G. Acute graft versus host disease: pathophysi-
outcomes in bone marrow transplant recipients: a population- ology, risk factors, and prevention strategies. Clin Adv Hematol
based cohort analysis. Crit Care. 2008;12(3):R77. Oncol. 2005;3:415-419, 428.
11. Paz HL, Crilley P, Weinar M, et al. Outcome of patients requiring 23. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host
medical ICU admision following bone marrow transplantation. disease. Lancet. 2009;373:1550-1561.
Chest. 1993;104(2):527-531. 24. Matzinger P. The danger model: a renewed sense of self. Science.
12. Naeem N, Eyzaguirre A, Kern JA, et al. Outcome of adult umbil- 2002;296:301-305.
ical cord blood transplant patients admitted to a medical inten- 25. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of
sive care unit. Bone Marrow Transplant. 2006;38(11):733-738. therapy for acute graft-versus-host disease: initial treatment.
13. Afessa B, Tefferi A, Hoagland HC, et al. Outcome of recipients Blood. 1990;76:1464-1472.
of bone marrow transplants who require intensive-care unit 26. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations
support. Mayo Clin Proc. 1992;67(2):117-122. of graft-versus-host disease in human recipients of marrow
14. Jackson SR, Tweeddale MG, Barnett MJ, et al. Admission from HL-A-matched sibling donors. Transplantation. 1974;18:
of bone marrow transplant recipients to the intensive care 295-304.
unit: outcome, survival and prognostic factors. Bone Marrow 27. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplanta-
Transplant. 1998;21(7):697-704. tion (first of two parts). N Engl J Med. 1975;292:832-843.

Section07-O-ref.indd 1 1/21/2015 11:26:51 AM